GSK to get less from Zhifei shingles vaccine deal; to collaborate on RSV
China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...
GSK expands deal with China's Zhifei to explore RSV vaccine collaboration
GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...
BioSpace16h
Moderna’s RSV Vaccines Run Into Safety Roadblock
The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
FiercePharma6d
GSK cuts Shingrix deliveries in revised Zhifei China pact, moves closer to RSV vaccine deal
Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...
GSK Expands Vaccine Collaboration With Zhifei in China
GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.
RSV prophylactic market to reach $6.2bn in 8MM by 2030
Six products in late-stage development have the potential to launch by 2030. Credit: MargJohnsonVA via Shutterstock. · ...
Yahoo Finance6d
GSK Expands Vaccine Collaboration With Zhifei in China
GSK plc GSK announced that it has revised its collaboration deal with Chongqing Zhifei Biological Products (Zhifei), China's largest vaccine maker, to co-market its shingles vaccine Shingrix in ...
Pharmabiz6d
GSK and Zhifei revise and extend strategic vaccine collaboration in China
GSK and Zhifei revise and extend strategic vaccine collaboration in China: London, UK Friday, December 6, 2024, 10:00 Hrs [IST] GSK plc announced that it has entered into an agree ...